In an FGFR-inhibitor-resistant SNU16R-derived xenograft mouse model, knocking out Bcl-2-associated athanogene-3 (BAG3) boosted antitumor effectiveness of infigratinib, suggesting a new therapeutic strategy for GC [72]. Here, BAG3 is linked to gastric cancer.